

## Special Issue

# The Changing Paradigms in the Management of Thyroid Cancer

### Message from the Guest Editor

In recent years, our understanding of thyroid cancer—including the differentiated, anaplastic, and medullary subtypes—has significantly advanced, largely due to discoveries regarding the molecular mechanisms driving tumor development, proliferation, and survival. Simultaneously, thyroid cancer incidence has risen, prompting a shift toward personalized treatment approaches rather than a standardized strategy. Active surveillance is increasingly being recognized as a viable option for managing low-risk differentiated thyroid cancers, alongside less invasive surgical techniques and selective radioiodine use. Meanwhile, new and highly selective targeted therapies are offering new hope for patients with aggressive thyroid cancers, including metastatic and anaplastic cases. This Special Issue will explore the evolving treatment landscape, highlighting innovative therapeutic strategies that are shaping current clinical practices, as well as future treatment paradigms.

---

### Guest Editor

Dr. Antonio M. Matrone

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, 56124 Pisa, Italy

---

### Deadline for manuscript submissions

closed (30 April 2026)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/235927](https://mdpi.com/si/235927)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)